FDA Shouldn't Keep Safe Drugs off the Market
By David Henderson
Enter Covid-19, the disease caused by the new coronavirus, SARS-CoV-2. There are no proven therapies to treat an infection of that virus. One of the most promising candidates is Gilead Sciences ’ remdesivir, which has shown some potential in treating other coronaviruses, such as SARS and MERS. Due to its use in treating Ebola infections, remdesivir is known to be generally safe.
With the FDA’s two-hurdle requirement in place, however, remdesivir must be proven effective in clinical trials before it can be sold for widespread use in Covid-19. These clinical trials take time, and they still won’t answer many of the questions doctors have about the drug’s use against Covid-19 now. What’s the right dose to get remdesivir into the lungs? How early should it be given? If it is given to sick patients already on ventilators in hospitals, will it help? All these things will depend on the individual patient.
This is from Charles L. Hooper and David R. Henderson, “FDA Shouldn’t Keep Safe Drugs Off the Market,” Wall Street Journal, March 25 (March 26 print edition.)
Read the whole thing if you subscribe. I will post the whole thing in 30 days, the amount of time I’m contractually obligated to wait.